Human MMP-9(Matrix Metalloproteinase 9) ELISA Kit
中文名称：人基质金属蛋白酶9(MMP-9)酶联免疫吸附测定试剂盒
Price:
- 反应性： Human
- 检测范围： 0.16-10 ng/mL
- 灵敏度： 0.1 ng/mL
| 产品应用 | ELISA |
| 检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗人MMP-9抗体包被于酶标板上，实验时样品（或标准品）中的人MMP-9会与包被抗体结合。后依次加入生物素化的抗人MMP-9抗体和辣根过氧化物酶标记的亲和素，抗人MMP-9抗体与结合在包被抗体上的人MMP-9结合，生物素与亲和素特异性结合而形成免疫复合物，游离的成分被洗去。加入显色底物(TMB)，TMB在辣根过氧化物酶的催化下呈现蓝色，加终止液后变成黄色。用酶标仪在450 nm波长处测OD值，MMP-9浓度与OD450值之间呈正比，通过绘制标准曲线计算出样品中MMP-9的浓度。 |
| 反应类型 | Sandwich-ELISA |
| 规格 |
96 T
/ 48 T
/ 96 T × 5
|
| 反应时间 | 3 h 30 min |
| 反应性 | Human |
| 检测方法 | 比色法;ELISA;夹心法 |
| 检测范围 | 0.16-10 ng/mL |
| 灵敏度 | 0.1 ng/mL |
| 样本体积 | 100 μL |
| 样本类型 | 血清、血浆或其他生物体液 |
| 特异性 | 可检测样本中的人MMP-9，且与其它类似物无明显交叉反应 |
| 精密度 | 板内，板间变异系数均<10% |
| 回收率 | 80%-120% |
| 储存条件 | 2-8℃ |
| 有效期 | 12个月 |
| 数据处理 |
-
Lipoxin A4 suppresses neutrophil extracellular traps formation through the FPR2-dependent regulation of METTL3 in ischemic stroke
IF: 3.500 -
Association of Serum Macrophage Migration Inhibitory Factor with 3-Month Poor Outcome and Malignant Cerebral Edema in Patients with Large Hemispheric Infarction
IF: 3.100Journal： Neurocritical Care (2024)Reactivity：HumanSample Type：serum -
Microbiological and Salivary Biomarkers Successfully Predict Site-Specific and Whole-Mouth Outcomes of Nonsurgical Periodontal Treatment
IF: 3.000Journal： Journal of Clinical Medicine (2024)Reactivity：HumanSample Type：saliva -
High-intensity intermittent exercise increases serum levels of chitinase 3-like protein-1 and matrix metalloproteinase-9 in persons with multiple sclerosis
IF: 2.900Journal： JOURNAL OF NEUROIMMUNOLOGY (2024)Reactivity：HumanSample Type：serum -
Apigenin inhibits epithelial mesenchymal transition in renal tubular epithelial cells through PI3K/AKT and NF-κB pathways for treating renal fibrosis
IF: 2.600 -
White Tea Consumption Alleviates Anthropometric and Metabolic Parameters in Obese Patients
IF: 2.400 -
Neurturin gene IVSI-663 polymorphism but not RET variants is associated with increased risk for breast cancer
IF: 1.000 -
Combined neurokinin-1 receptor antagonist and sorafenib is a promising approach for hepatocellular carcinoma therapy
IF: 0.800 -
CREB1-driven CXCR4hi neutrophils promote skin inflammation in mouse models and human patients
IF: 16.600 -
Mechanisms of Antitumor Invasion and Metastasis of the Marine Fungal Derivative Epi-Aszonalenin A in HT1080 Cells
IF: 5.400
实验操作视频
